Since our founding in 2002, we’ve grown from a small R&D operation in Southern California to a multinational clinical cell treatment provider with a robust pipeline of products targeting several inflammatory diseases. Based on a foundation of research spanning two decades and reinforced by numerous proprietary processes and patented technologies, our stemXcell platform focuses our therapies on treating inflammation, the root of most diseases, giving PrimeGen Global a distinct advantage over other cell therapy companies. Starting with potent, high-quality stem cells developed in line with strict United States Food and Drug Administration’s GMP guidelines, we apply our patented techniques to jumpstart the immunomodulatory properties of our cells prior to patient administration. This process allows us to focus the cells on serving a specific function in the treatment of different disease types. Today, we’re in the process of preparing our allogeneic stemXcell treatments for clinical trials in the USA and in China, where they will be used to treat acute and chronic liver disease. With a long history of innovation and stem cell industry firsts, our scalable and flexible stemXcell treatment platform and growing manufacturing and clinical capabilities, PrimeGen Global is positioned to make cell therapies a mainstay of modern medicine.
